US FDA accepts AMAG's resubmission of Feraheme for anaemia
This article was originally published in Scrip
Executive Summary
The US FDA has accepted AMAG Pharmaceuticals' resubmission of its lead candidate, Feraheme (ferumoxytol injection) – an iron replacement treatment for iron deficiency anaemia in chronic kidney disease – following its complete response letter in December.